Clinical trial ODO-TE-B301, CONTESSA
A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Women with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Odonate |
| EudraCT Identifier | 2017-002961-23 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03326674 |
| Inclusion criteria | 2nd line metastatic RECIST 1.1 HER2 negative Hormono positive |
| Last update |